EXEL EXELIXIS, INC.

EXEL financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 939767 Exchange: Nasdaq SIC: 2836 (Biological Products, (No Diagnostic Substances))
Showing 3 of 19 annual and 0 of 64 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Large accelerated filer
Entity Type
Operating
Public Float
$9.40B (Jul 2025)
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Incorporated
DE
Fiscal Year End
January (0101)
Phone
6508377000
EIN
043257395
Headquarters
ALAMEDA, CA, 94502
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: EXELIXIS INC (2000–2012)

▼ Key Metrics (TTM)

As of Jul 3, 2026
Financials
Revenue
$2.44B
Net Income
$860.62M
Total Assets
$2.49B
Total Equity
$1.84B
Total Debt
-
Free Cash Flow
$1.17B
Ratios
Gross Margin
96.5%
Operating Margin
39.9%
Net Margin
35.3%
Return on Equity
46.7%
Return on Assets
34.5%
Current Ratio
3.46x
FCF / Assets
47%

▼ FY 2025 Summary Analysis

Annual report ending Jan 2, 2026

Overview and Growth

EXELIXIS, INC. generated $2.32B of revenue in fiscal 2025, with net income of $782.57M and an operating cash inflow of $884.27M. At $2.32B, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. The top line expanded 7.0% from $2.17B in fiscal 2024, increasing the company’s operating scale. The company reported diluted EPS of $2.78, adding a shareholder-level measure to the absolute income figures considered below. The per-share result recorded a 58.0% increase from fiscal 2024 diluted EPS of $1.76. The company employed $2.84B of total assets, the balance-sheet base supporting its current operating and cash-flow results. The revenue-to-assets relationship was 0.82x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

Gross profit was $2.24B, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. Gross margin was 96.4%, so that share of each revenue unit remained after the cost of revenue reported for the period. The reported operating result was $872.19M, capturing profitability after direct costs and the operating expenses reflected in the statements. Relative to revenue, operating income represented 37.6%, showing how efficiently sales converted into operating profit. After all reported below-operating-line items, the company recorded net income of $782.57M for the fiscal year. Measured against reported revenue, net income produced a 33.7% margin after operating costs and the remaining recognized items. Income tax expense totaled $158.64M, providing the reported tax component that separates pretax and after-tax earnings. The relationship between net income and period-end equity was 36.2%, indicating the profitability achieved on book capital. Return on period-end assets was 27.5%, connecting net income with the company’s total asset base. Against $521.27M in fiscal 2024, the current $782.57M bottom line finished above the prior-year result in absolute terms.

Liquidity and Capital Structure

At period end, the $2.84B asset base was financed through $683.10M of liabilities and $2.16B of equity. The near-term balance sheet paired $1.44B of current assets with $405.64M of current liabilities at the reporting date. The current ratio was 3.56x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Cash and equivalents totaled $482.49M, identifying the most liquid reported component available within the broader current-asset balance. The cash balance equaled 118.9% of current liabilities, showing how much near-term coverage came from cash alone. The liabilities-to-assets relationship was 24.0%, placing reported obligations against the full positive asset balance. Measured against total assets, cash and equivalents represented 17.0%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 3.5% from $2.95B in fiscal 2024, leaving current total assets lower year over year. Against $2.24B of equity in fiscal 2024, the current book-equity balance moved 3.7% and ended lower. The reported cash balance changed 122.0% from $217.37M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

Cash flow from operations was $884.27M, a reported cash inflow that can be compared directly with net income and capital spending. The operating-cash-flow-to-net-income relationship was 1.13x, comparing cash generated by operations with the bottom-line earnings result. Capital spending was $8.43M, absorbing part of the cash generated from operations before free cash flow. Capital expenditures represented 1.0% of operating cash flow, leaving the remainder available as free cash flow. The combination of operating cash flow and capital spending produced $875.84M of positive free cash flow for the period. Relative to revenue, free cash flow equaled 37.7%, showing how much sales converted into cash after investment. Measured against total assets, free cash flow represented 30.8%, showing the cash productivity of the company’s assets.
Based on the annual report for the fiscal year ending Jan 2, 2026. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual (FY)
Quarterly 🔒
Chart 🔒
Annual financial statements for EXELIXIS, INC.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $2.32B $2.17B $1.83B
Cost of Revenue $83.70M $76.22M $72.55M
Gross Profit $2.24B $2.09B $1.76B
OPERATING EXPENSES
R&D Expense $825.00M $910.41M $1.04B
SG&A Expense $518.73M $492.13M $542.71M
Other Operating Expenses (derived) $20.51M $85.33M $0
Operating Income $872.19M $604.62M $170.89M
NON-OPERATING INCOME / EXPENSE
Interest Income $69.21M $77.16M $86.54M
Other Income/Expense $-198.00K $-133.00K $93.00K
Income Tax $158.64M $160.37M $49.76M
Net Income $782.57M $521.27M $207.77M
PER SHARE & SUPPLEMENTAL
Diluted EPS $2.78 $1.76 $0.65
Diluted Shares 281.86M 296.13M 321.46M
EBITDA $901.25M $633.42M $196.60M
Depreciation & Amortization $29.06M $28.80M $25.72M
Balance Sheet
ASSETS
Cash & Equivalents $482.49M $217.37M $262.99M
Short-term Investments $576.60M $893.90M $732.31M
Accounts Receivable $286.92M $265.44M $237.41M
Inventory $21.69M $22.39M $17.32M
Other Current Assets $75.60M $68.48M $67.93M
Current Assets $1.44B $1.47B $1.32B
PP&E (Net) $98.96M $119.39M $128.73M
Goodwill $63.68M $63.68M $63.68M
Noncurrent Assets $1.40B $1.48B $1.62B
Total Assets $2.84B $2.95B $2.94B
LIABILITIES
Accounts Payable $29.62M $38.19M $33.77M
Other Current Liabilities $125.38M $95.01M $108.42M
Current Liabilities $405.64M $403.77M $394.28M
Other Noncurrent Liabilities $104.42M $108.90M $94.22M
Noncurrent Liabilities $277.46M $299.72M $284.17M
Total Liabilities $683.10M $703.49M $678.45M
EQUITY
Common Stock $262.00K $282.00K $303.00K
Additional Paid-in Capital $2.23B $2.34B $2.44B
Retained Earnings $-76.83M $-98.65M $-173.35M
Accumulated OCI $3.48M $-1.35M $-3.75M
Total Equity $2.16B $2.24B $2.26B
Total Liabilities & Equity $2.84B $2.95B $2.94B
SUPPLEMENTAL
Shares Outstanding 262.48M 281.73M 302.79M
Check: A − (L + E + NCI) - - -
Cash Flow Statement
Cash from Operations $884.27M $699.97M $333.32M
Capital Expenditures $8.43M $28.44M $40.47M
Cash from Investing $350.44M $-116.78M $-26.96M
Cash from Financing $-969.59M $-628.81M $-546.05M
Free Cash Flow $875.84M $671.54M $292.86M
Beginning Cash (CFS) $217.37M $262.99M -
Net Change in Cash $265.11M $-45.62M -
Effect of FX on Cash - - -
Calculated Ending Cash $482.49M $217.37M -
Cash per BS $482.49M $217.37M $262.99M
Cash scope difference (CFS − BS) - - -
Cash per CFS $482.49M $217.37M $262.99M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is EXELIXIS, INC.'s annual revenue?

EXELIXIS, INC. reported $2.44B in revenue for trailing twelve months (ending July 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is EXELIXIS, INC. profitable?

Yes. EXELIXIS, INC. reported $860.62M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does EXELIXIS, INC. generate free cash flow?

Yes. Free cash flow was $1.17B for trailing twelve months. Operating cash flow was $1.18B.